AGEN Agenus Inc

$AGEN Now lets see a few more country's jump on the wagon to allow Bot Bal to be available in there countries and save many lives. Get ready. These numbers are unbelievable. Bot Bol #1 in the world as of today for mCRC and more.

$AGEN --B. Riley Adjusts Agenus Price Target to $16 From $14, Maintains Buy Rating MT NEWSWIRES 7:37 AM ET 11/9/2026

$AGEN you can only keep it down so long. Look at the stats !! Look at the earnings report and now commercial income everything heading in a positive direction.

$AGEN Great close! More solid data, very positive fireside chat and revenue annualizing over $20 million, which very few would have expected this time last year. That being said, TGIF. Time for wine.

$AGEN -breakdown of the ESMO real-world evidence (Poster 3771P) in advanced sarcoma: > 24% ORR & 68% DCR in heavily pretreated patients with relapsed/refractory metastatic sarcoma. Unheard of. > Efficacy After Prior ICI Failure: Delivered partial responses and durable stabilization in patients who previously progressed on standard checkpoint inhibitors. > Broad Activity: Clear signal across difficult-to-treat vascular sarcomas (Angiosarcoma, Kaposi) and ultra-rare subtypes (Chordoma, Epithelioid). > Botensilimab’s Fc-enhancement continues to demonstrate meaningful clinical benefit where traditional CTLA-4/PD-1 regimens stall. Real-world validation is piling up

$AGEN This is primed for a run and then very attractive for a BO. Whomever buys this company would surely want to buy before commercialization and revenue income materializes. The results are outstanding and probably even better when the potential buyer gets to "peak under the skirt." The good doctor is fading into the background and allowing his son to reap the praise and reward that will surely come. Our time is coming, sure as sh.t. GLTA

$AGEN Keep counting pennies while the vault is being loaded. Y’all sitting here crying on Stocktwits, calculating "10M dilution from this option" and "10M from that warrant," completely blind to what just landed at #ESMO26. While retail is hyper-focused on daily volume and accounting noise, Big Pharma is eyeing an Fc-enhanced CTLA-4 platform backed by $340M in institutional capital. This isn't a penny play it’s a $5B–$10B M&A target waiting on interim Phase 3 data. Keep day-trading the noise. The adults are waiting for the buyout wire.

$AGEN Why did they not announce today's news last night on the call? Give it its own highlight? The results are very very strong. I can't believe the market cap. It should be at least double. If Garo didn't suck, it would be at least $1B market cap.

$AGEN repeating this..$AGEN Remember that with an implied share number of 140m, at a SP of 7, the market cap is really about 980. (45m shares outstanding plus 77m deep in the money options, plus some incentive options.) This may be a 5B drug and company in 4 years after P3 trials, but that is a long time from now. (And I am long).

$AGEN So, cash is there, Investment is there, quality clinicians are on board, and results are through the roof.....this should really get those "in the know" to sit up and take notice. Only a matter of time until we wake up some morning and find the price skyrocketing into the high double digits. Tick tock.

$AGEN It is a platform with potential across several indications, and evidence continues to accumulate.

$AGEN Rodman and Renshaw fire side chat was great. I think that Bot/Bali story is getting a lot more attention. Memorial Sloan Kettering is doing rectal cancer neo-adjuvant IST. This might be a first opportunity to gain an AA due to severity of current treatments. Robin is a really stand up guy and well spoken. Apparently there is a lot of interest in Robbin Phase 3 participation, and they are focusing on high volume sites that can recruit patients rapidly. My gut feeling is that we might see a rapid recruitment on e the study starts.

$AGEN Good morning, Lets clear this out, data that came out at ESMO for IPI/NIVO is for MSI-H CRC, and Agenus reported nearly identical data in MSS CRC (Cold tumors). Lets stop comparing the two studies, because they are not same. Chalabi wouldn't use Bot/Bali if Brystol Myers had a solution.

$AGEN Susie Wiles storyis getting interesting Ibrx board seems to think she had influence With large pharma

$AGEN Mice email from Zack today Results on website I couldn’t fit it all But I added The bottom here They are talking to more analysts !!! Finally get noticed Later this week (Thursday, Nov. 5th from 11:30am-12pm EST) we will be conducting a virtual fireside chat with Mike King at Rodman & Renshaw, where we will be discussing these updated findings in the context of our upcoming ROBBIN Phase 3 trial, and key catalysts in the upcoming year. You can register for the fireside chat HERE. This follows a fireside chat that we had with Andreas Argyrides at Chardan during their healthcare conference last month, where Dr. Ben Schlechter from the Dana Farber Cancer Institute joined me in discussing our data in neoadjuvant Stage II/III MSS colon cancer and the upcoming ROBBIN trial. A replay of that fireside chat can be viewed on our website HERE. Best, -Zack

$AGEN Stop rushing. You are part of the problem. The market doesn't reward the impatient. Let’s get real for a second, the fundamentals didn’t change, the ESMO data is stellar, and the science is solid.Selling out of panic or crying because the stock didn’t 10x in a single pre-market session just plays right into the hands of the algorithms and market makers. Biotech isn't a scratch-off ticket, it's a chess game.

$AGEN Interesting post on LinkedIn by #AGEN this morning. To my untrained eye, they look like awesome results.

$AGEN This data release kind of changes the clinical picture for bot/bal for me. This is a dMMR study so it’s a hot tumor. The bar was set extremely high by ipi/nivo with zero recurrence over 200+ pts. Bot/bal matched efficacy endpoints (mps, cr) but had two recurrences at 15 months. DFS is a fairly important endpoint so from the perspective of will bot/bal improve on Niche in dMMR I think the answer is no. Which leads me to think BOT's engineered Fc activity might add relatively little in an already immunogenic dMMR tumor but make a substantial difference in an immune-resistant pMMR tumor. There is one more loose thread which is dose. Neoasis used 50mg and niche had 75mg. Robbin will use and nest used 75mg, so it’s possible this is a dose issue.

$AGEN Just thinking about Oncology Analysts/Journalists such as Feuerstein and Plieth. They are by some considered “ Biotech bashers” as they frequently post deeply negative reviews of trials and companies ( including many dismal reviews of Agenus and Garo ). Have they ever posted anything suggesting Agenus’s Bot/Bal is a promising combo that could help save lives and improve quality of life for those who are suffering from “cold” tumors that are unresponsive to past treatments? I understand if they strictly present a business description as to how likely approval can be anticipated but they certainly have reviewed studies of Bot/ Bal and I do not recall any positive feedback on how this combo is showing efficacy in areas badly needed. Maybe they are only doing this for investors and $$ and helping patients is not a concern.

$AGEN Magic. I am not writing them off. I am invested heavily in $SMMT too. It’s just that ivo and Akeso’s PD-L1/CTLA4 bispexific are not competing wirh bot/bal. The trials are in MSI-H/dMMR colon cancer. Different animal.